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Abstract
Introduction: Effective antihypertensive therapy reduces the risk of cardiovascular and cerebrovascular disease and death. Perindopril,
a long-acting angiotensin-converting enzyme (ACE) inhibitor, is an established antihypertensive agent administered as a once-daily
tablet. 
Aims: To review recent evidence for the use of perindopril in the treatment of hypertension.
Evidence review: Evidence shows that perindopril alone or in combination with other antihypertensive agents can achieve clinically
significant reductions in blood pressure after 12 weeks of treatment. There is strong evidence from large randomized studies that
perindopril-based therapy reduces the risk of cardiovascular outcomes, including mortality, in patients with coronary artery disease and
those who have had a prior stroke or transient ischemic attack. There is also some evidence that these effects are greater than those
achieved by blood pressure reduction alone, suggesting other drug-related effects including improvements in endothelial function.
Recent results have also shown that an amlodipine ± perindopril regimen prevented more major cardiovascular events than an 
atenolol-based regimen in patients with hypertension, as a result of better control of blood pressure. Economic evidence from one major
study shows that, for most patients, the incremental cost per quality-adjusted life-year gained with perindopril 8 mg was lower than the
threshold value of €20 000 (73–92% of patients) in Europe or £20 000 (94% of patients) in the UK.
Clinical value: There is strong evidence supporting the use of perindopril-based therapy for the treatment of hypertension and reduction
in the risk of cardiovascular disease, stroke, and death in a wide range of patients with stable coronary artery disease or hypertension. 
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Core evidence clinical impact summary for perindopril in hypertension
Outcome measure Evidence Implications
Patient-oriented evidence
Reduction in cardiovascular mortality  Clear  Control of blood pressure reduces risk of death
Avoidance of cardiovascular events 
(MI, CHF)
Clear Control of blood pressure reduces risk of comorbidities
Avoidance of cerebrovascular 
events (stroke)
Moderate  Reduced risk of subsequent stroke, disability, and dependence 
Effective as single daily dosing  Clear Convenient administration as monotherapy or combination
Disease-oriented evidence
Clinically significant reduction in 
systolic and diastolic blood pressure
Clear Sufficient control for avoiding cardiovascular and cerebrovascular events
Improvement in endothelial dysfunction  Limited  Perindopril may have antiatherosclerotic properties in addition to 
antihypertensive effects
Economic evidence
Cost effectiveness Limited  Emerging evidence. Reduction of risk of comorbidities likely to benefit resource use.
Further studies required
CHF, congestive heart failure; MI, myocardial infarction.
     Scope, aims, and objectives
Hypertension is a major but modifiable contributory factor in
cardiovascular diseases (CVDs) such as stroke and coronary
heart disease (CHD). As such, hypertension is one of the most
important preventable causes of premature death in both
developed and developing regions (Ezzati et al. 2002).
Several classes of antihypertensive drug are currently available
for the management of hypertension including diuretics and beta
blockers and newer agents such as calcium channel blockers
(CCBs) and angiotensin-converting enzyme (ACE) inhibitors.
Perindopril (Aceon®, Coversyl®) is a long-acting lipophilic 
ACE inhibitor developed for treating hypertension. The main 
goal of antihypertensive treatment is not to reduce blood
pressure per se, but to prevent complications associated with
hypertension such as cardiovascular and cerebrovascular
disease, reduce mortality, and improve quality of life. The aim 
of this article is to review the evidence for the clinical impact 
of perindopril in the treatment of hypertension and reduction of
associated complications.
Methods
English language medical literature databases were searched 
for appropriate articles relating to the treatment of hypertension 
and symptomatic heart failure with perindopril. A literature search 
was conducted on October 3, 2005 using the search terms
“perindopril AND hypertension” for articles published between
January 1990 and September 2005 (inclusive):
• PubMed, http://www.ncbi.nlm.nih.gov/entrez
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE),
http://www.york.ac.uk/inst/crd/darehp.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• National Guideline Clearinghouse, http://www.guideline.gov
Four sets of current clinical guidelines were identified and after
removing duplicates a total of 318 articles (full publications and
meetings abstracts identified using the above databases) were
retrieved and any animal, in-vitro, and non-English-language
articles were excluded. An updated search using the same terms
was performed in September 2006; this search identified six
additional articles to be included.
Table 1 summarizes the levels of evidence of the 33 articles
(guidelines excluded) selected from the 324 articles identified by
the search strategy. One systematic review and meta analysis
was identified for inclusion; most of the evidence base comprised
level 2 clinical evidence. One meeting abstract reporting
economic evidence was found. In addition, one further article 
(a meeting abstract reporting economic evidence) was provided
by the manufacturer (Servier) on January 13, 2006 and included.
Therefore a total of 34 articles were included in the final 
evidence base. 
Disease overview
Hypertension is a chronic, age-related disorder which may lead to
serious and disabling cardiovascular, cerebrovascular, and renal
complications. The consensus definition of hypertension is blood
pressure of  ≥140/90 mmHg [i.e. either systolic blood pressure
(SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg]
in adults over 18 years of age (Chobanian et al. 2003; ESH/ESC
2003; NICE 2006; Williams et al. 2004). 
Hypertension is the most common primary diagnosis in the 
USA with 35 million office visits each year and it accounts for
about 20% of family practitioners’ annual consultations in the 
UK (Chobanian et al. 2003; NICE 2006). More than 60% of
Americans aged 65 years and older have hypertension and
estimates of the cost of its treatment range from $US7 billion to
$US14 billion per year (Fischer & Avorn 2004). It was estimated
that the total number of adults worldwide with hypertension in
2000 was 972 million; 333 million in economically developed
countries and 639 million in developing countries (Kearney et al.
2005). Thus almost a quarter of the world’s adult population were
judged to have hypertension in 2000; by 2025 this proportion is
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Category Number of records
Full papers Abstracts
Initial search 268 50
records excluded 245 46
records included 23 4
Search update, new records 5 1
Additional studies identified 0 1
Level 1 clinical evidence 1 0
Level 2 clinical evidence 18 2
Level ≥3 clinical evidence 92
trials other than RCT 0 0
case studies 0 0
Economic evidence 0 2
Total records 28 6
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial. 
Table 1 | Evidence base included in the review65
predicted to reach 29% (affecting 1.56 billion adults) assuming
that country-, age-, and gender-specific prevalence estimates
remain constant. 
The most common form of hypertension, essential or primary
hypertension, has no single identifiable cause. However, the
inability of the kidney to excrete sodium at normal blood pressure
plus contributions from the central nervous system, endocrine
factors, large arteries, and the microvasculature all have roles in
the development of this disorder (Staessen et al. 2003).
Although it is only one of several risk factors for CVD (Padwal et al.
2001), hypertension increases an individual’s risk of various
cardiovascular complications [e.g. stroke, congestive heart failure
(CHF), CHD] approximately two- to three-fold. Furthermore,
hypertension is implicated in 35% of all atherosclerotic
cardiovascular events including 49% of all cases of heart failure
(Padwal et al. 2001). As blood pressure increases so does the risk
of myocardial infarction (MI), stroke, heart failure, and renal disease.
For example, between the ages of 40–69 years each difference of
20 mmHg from usual SBP (or 10 mmHg from usual DBP) is
associated with double the death rate from stroke, ischemic heart
disease, or other vascular causes (Lewington et al. 2002). 
Estimates of CVD risk are most accurate when major risk factors
are evaluated using risk functions derived from epidemiologic
studies (e.g. Framingham risk function) (Williams et al. 2004).
These risk factors should be considered in conjunction with blood
pressure levels in determining appropriate treatment for patients
with hypertension. Examples of thresholds for initiating
treatments according to blood pressure and CVD risk factors
outlined in current guidelines are summarized in Table 2. 
Since it is a significant modifiable risk factor for CVD, a number of
large studies have shown that the burden of hypertension can be
addressed by successful reductions in blood pressure. Treatment
with any commonly used antihypertensive regimen reduces the
risk of total major cardiovascular events, and larger reductions of
blood pressure achieve larger reductions in risk (Turnbull 2003).
For example, the Hypertension Optimal Treatment (HOT) trial
showed that intensive lowering of blood pressure in patients with
hypertension was associated with a lower rate of cardiovascular
events (Hansson et al. 1998). The lowest incidence of major
cardiovascular events occurred at a mean achieved DBP of 
82.6 mmHg and the lowest incidence of cardiovascular mortality
occurred at 86.5 mmHg. In addition, antihypertensive therapy has
been shown to be associated with mean reductions of 35–40% 
in the incidence of stroke, 20–25% reductions in MI, and more
than 50% reduction in heart failure (Neal et al. 2000). 
The Heart Outcomes Prevention Evaluation (HOPE) studies have
also provided evidence that treatment with an ACE inhibitor (ramipril)
reduces cardiovascular event rates in a high-risk population (Yusuf
et al. 2000). In over 9000 high-risk patients [>55 years old with a
history of previous stroke, peripheral vascular disease, coronary
artery disease (CAD), or diabetes, plus other risk factors] active
therapy for a mean of 5 years reduced the combined rate 
of cardiovascular death, MI, and stroke by 22% (P<0.001). Active
treatment also reduced the rates of death from cardiovascular
causes by 26%, the risk of MI by 20%, and the risk of stroke 
(all  P<0.001). These outcomes were achieved with a modest
reduction in blood pressure (SBP/DBP reduction 3.3/2.0 mmHg).
Current therapy options
The goal of antihypertensive therapy is the long-term reduction of
cardiovascular morbidity and mortality. In patients with
hypertension, the optimal blood pressure treatment goal is SBP
<140 mmHg and DBP <90 mmHg; for diabetic patients with
hypertension the target blood pressure goal is SBP <130 mmHg
and DBP <80 mmHg (Chobanian et al. 2003; ESH/ESC 2003;
Williams et al. 2004). Drug-based and nondrug therapies may be
used to achieve these goals.
It is beyond the scope of this article to review all the current
agents and recommendations for the treatment of hypertension,
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Guideline  SBP ≥140–159 mmHg or
DBP ≥90–99 mmHg
SBP ≥160 mmHg or
DBP ≥100 mmHg
Reference 
JNC-7 Treat with single drug or combination  Treat with two-drug combination Chobanian et al. 2003
ESC/ESH Monitor and consider treatment in 
low-/moderate-risk patients. Treat high/
very-high-risk patients 
Treat all patients with BP 
>180/110 mmHg
ESC/ESH 2003
BHS Treat if patients also have 10-year CVD 
risk ≥20% or existing CVD or target 
organ damage, otherwise observe and
reassess annually
Treat all patients  Williams et al. 2004
NICE Treat if patients also have raised CV 
risk (10-year risk of CHD ≥15% or CVD 
risk ≥20% or existing CVD or target 
organ damage)
Treat all patients  NICE 2006
BHS, British Hypertension Society; BP, blood pressure; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; ESC/ESH, European
Society of Hypertension-European Society of Cardiology; JNC-7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure;
NICE, National Institute for Health and Clinical Excellence; SBP, systolic blood pressure. 
Table 2 | Thresholds for initiating antihypertensive treatment in nondiabetic patients according to current guidelinesand comprehensive guidelines have recently been published for
the USA (Chobanian et al. 2003), UK (NICE 2006; Williams et al.
2004), and Europe (ESH/ESC 2003). However, there are several
classes of drug commonly used to control hypertension and these
include thiazide-type diuretics, CCBs, beta blockers, angiotensin
receptor blockers (ARBs), and ACE inhibitors. The choice of drug
depends on the individual patient’s clinical profile, but most
patients will require combination therapy (Chobanian et al. 2003;
Williams et al. 2004).
The foundation of successful management of high blood pressure
is the adoption and adherence to healthy lifestyles in all patients
with hypertension. Lifestyle modifications can reduce the need 
for drug therapy or may complement the efficacy of existing drug
regimens, and can have a favorable influence on overall CVD risk
(Chobanian et al. 2003; ESH/ESC 2003; NICE 2006; Williams et al.
2004). However, changes to lifestyle alone are rarely sufficient for
the long-term control of hypertension. 
Low-dose combination therapy is increasingly being recommended
in national and international guidelines for initial treatment of
hypertension (de Leeuw 2001). The most important reason 
to combine two or more classes of antihypertensive drug is to
obtain enhanced blood pressure control with good tolerability. 
In addition, a combination of drugs is likely to be of greater benefit
when one drug avoids or counteracts compensatory mechanisms
elicited by the other drug (de Leeuw 2001). However, not all
combinations of drug are effective or well tolerated. Typical
combinations of drugs include an ACE inhibitor with a CCB or a
diuretic, an ARB with a diuretic, and a beta blocker with a diuretic
(Chobanian et al. 2003). 
Unmet needs
Although control rates for hypertension have improved, about
30% people in the USA are still unaware that they may be
hypertensive, partly because of its asymptomatic nature
(Chobanian et al. 2003). In addition, substantial underdiagnosis,
undertreatment, and poor rates of control exist in the UK 
(Williams et al. 2004). The serious consequences of failure to
control hypertension are well understood. 
Nonadherence to therapy is a major contributor to poor control.
Because of the lack of symptoms, patients may misunderstand the
nature of the condition and the necessary treatment and may
perceive the need for medication as a symbol of ill health. 
In addition, tolerability issues can influence drug compliance.
Management of other comorbidities, common in older patients
and in those with other risk factors, will likely involve treatment with
other medications and the burden of polypharmacy or reduced
tolerability through interactions cannot be discounted. Therefore, 
a treatment that is convenient to administer (ideally once daily), 
is well tolerated (in combination with other antihypertensives and
additional medications), and is effective in reducing hypertension
and related morbidity and mortality, is likely to be beneficial in
addressing the undermanagement of this condition. 
ACE inhibitors are the only class of antihypertensive agent for
which there is clear evidence of benefit for all the comorbid
conditions listed in the JNC-7 (Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure) guidelines (i.e. heart failure,
post-MI, high coronary disease risk, diabetes, chronic kidney
disease, and recurrent stroke prevention) (Chobanian et al. 2003).
NICE guidelines recommend an ACE inhibitor as first-line
antihypertensive drug therapy in patients aged under 55 years
(NICE 2006). The choice of ACE inhibitor depends on a number of
factors, including frequency of dosing as influenced by
peak–trough ratio (Anon. 1997), and the ability to inhibit tissue ACE
(Dzau et al. 2001). 
Perindopril is an ester prodrug of the ACE inhibitor perindoprilat
that may be administered orally once daily because of its very 
high peak–trough ratio (>50% for doses ≥4 mg; reviewed in 
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Active drug Tissue potency ranka ACE inhibitor potency, 
ID50 (mmol/L x 10-9)
Plasma half-life (h) Relative lipophilicityb
Quinaprilat =1 0.07 25 ++
Benazeprilat =1 NA 11 +
Ramiprilat 3 0.08 >50 ++
Perindoprilat 4 0.40 10 ++
Lisinopril 5 NA 12 NA
Enalaprilat 6 1.00 11 +
Fosinoprilat 7 NA 11.5 +++
Captopril 8 15.00 2 +
aDetermined from radioligand-binding studies with the active drug moiety; bLipid solubility based on log P logarithm of the octanol/water partition coefficient of the active drug moiety 
(except for captopril); “+” indicates increasing lipid solubility. 
ACE, angiotensin-converting enzyme; ID50, the inhibitor concentration required to displace 50% of [125I]531A bound to human plasma angiotensin-converting enzyme; h, hour; NA, not available.
Table 3 | Physicochemical and pharmacologic characteristics of various ACE inhibitors (reprinted from Am J Cardiol, 88, Dzau et al.
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data, pp.11–20L. 
Copyright 2001, with permission from Elsevier)67
Hurst & Jarvis 2001). It has been shown that the relative tissue
affinity and lipophilicity of perindoprilat compares favorably with
other ACE inhibitors (Table 3). Perindopril has been shown to
effectively inhibit tissue ACE activity from endothelia and adventitia
(the connective tissue surrounding arteries and organs) 
(Zhou et al. 2002). Although it is generally accepted that
endothelial ACE is an important target for efficacy of any ACE
inhibitor, inhibition of adventitial ACE may be just as relevant,
particularly in the management of hypertension, heart failure,
and/or ischemic heart disease (Zhou et al. 2002). Therefore,
perindopril appears to fulfill a number of pharmacodynamic criteria
for an antihypertensive agent to support the effective treatment 
of this condition.
Clinical evidence with perindopril
Control of hypertension 
The clinical use of perindopril in controlling hypertension has been
studied in great detail for over 15 years and its effects have been
reviewed extensively (Lerebours & Antony 1994; Hurst & Jarvis
2001; Oparil 2001). Much of the existing evidence demonstrating
the antihypertensive effect of perindopril has been based on
randomized controlled trials that can be found in the
aforementioned reviews. This section will evaluate outcomes 
from systematic reviews, large open-label community and
postmarketing studies that have been published more recently
(i.e. since 2000). These studies confirm the existing evidence that
perindopril reduces blood pressure when used as monotherapy
as well as combination therapy (Table 4).
Monotherapy
There is clear evidence that perindopril given as monotherapy
significantly reduces SBP and DBP (from baseline values) in
patients with hypertension. 
A large, open-label, postmarketing surveillance study in France
involving patients with hypertension (DBP 95–114 mmHg) treated with
perindopril (2, 4, or 8 mg/day) showed that blood pressure reduction
was maintained after 1 year of treatment (Speirs et al. 1998). 
Mean blood pressure (SBP/DBP) fell from 173/100±16.23/8 mmHg 
in 47 253 patients starting the study to 145/82±12.2/8 mmHg in 
46 799 patients successfully completing treatment.
The efficacy of perindopril 4 and 8 mg has been evaluated in a
large, 12-week, community-based, open-label study involving 
13 220 patients with hypertension. All patients received perindopril
4 mg for the first 6 weeks; the dose was titrated to 8 mg after 
6 weeks in inadequately responsive patients. From baseline 
to week 12, blood pressure was reduced significantly 
from 156.9/94.5 mmHg to 139.2/84.0 mmHg (Julius et al. 2004). 
Blood pressure control was achieved in almost half (48.8%) of all
patients. In patients deemed inadequately responsive (n=4154),
dose titration to 8 mg daily resulted in a clinically significant
reduction in blood pressure and an increase in the proportion of
patients achieving blood pressure control (<140/90 mmHg) from
7.1% (at week 6) to 34.0% (by week 12).
A number of subpopulation analyses from this study showed that
perindopril monotherapy was effective regardless of sex, age, and
ethnicity (Cohn et al. 2004; Julius et al. 2004; Neutel et al. 2004).
A further analysis looked at a subgroup of patients whose blood
pressure was not controlled with previous antihypertensive
therapy (Guo et al. 2004). Physicians assessed that 73.8% of
patients in this population achieved a satisfactory therapeutic
response from perindopril treatment (Guo et al. 2004). 
Combination therapy
Although monotherapy is still the preferred option for the initial
treatment of hypertension, most patients will at some stage need
more than one drug to control their blood pressure. Indeed, 
low-dose combination therapy is becoming increasingly popular for
initial treatment. Treatment adherence may be enhanced when the
combination therapy is in a single dosage formulation, with obvious
advantages for the practicing physician and patient (Williams et al.
2004). Perindopril has been formulated with indapamide (a
nonthiazide sulfamoyl chlorobenzamide diuretic) as a combination
treatment for hypertension. Part of the rationale for using this
combination is that both components have a similar half-life, there is
no pharmacokinetic interaction between them, and the combination
can be formulated for administration as a once-daily tablet.
There is clear evidence from a meta analysis of 11 studies that 
the fixed low-dose combination of perindopril and indapamide
given as one tablet daily is effective as first-line treatment for
patients with mild-to-moderate hypertension (Table 4). The meta
analysis showed that in five studies with the combination versus
placebo, the between-group weighted mean differences (WMDs)
for both SBP and DBP favored perindopril plus indapamide 
(SBP –9.03 mmHg; DBP –5.09 mmHg; both P<0.01 for z score for
overall effect). In these studies the rates of normalization and
blood pressure response were 64.7–90.0% and 74.0–81.3%,
respectively, with treatment compared with 42.1–44.4% and
48.9%, respectively, with placebo (Kang et al. 2004).
In the six studies of the combination versus other antihypertensive
agents (e.g. perindopril monotherapy, perindopril plus low-salt diet,
enalapril, losartan, atenolol, irbesartan) the between-group WMDs
for both SBP and DBP also favored perindopril plus indapamide
(SBP –3.72 mmHg, P=0.03 for z score for overall effect; DBP 
–1.71 mmHg, P<0.01 for z score for overall effect). However, the
test for heterogeneity of SBP and DBP was statistically significant
between these different studies. Differences in design of the studies
and measurement methods for blood pressure may have
contributed to the heterogeneity (Kang et al. 2004). 
A notable component trial of the meta analysis was the Perindopril
pROtection aGainst REcurrent Stroke Study (PROGRESS)
(PROGRESS 2001). One of the many outcomes from this large
study involving 6105 patients (48% were hypertensive) was a
reduction in blood pressure. After 4 years of treatment with a
perindopril-based regimen (i.e. perindopril plus indapamide at the
physician’s discretion), blood pressure was reduced by 9/4 mmHg
compared with placebo treatment. When compared with placebo,
the reduction in blood pressure was greater among those treated
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Table 4 | Effect of perindopril on blood pressure in patients with hypertension 
Level of
evidence
Reference Design  Treatment  and 
mean dose 
Outcome
SBP DBP BP control 
(<140/90 mmHg)
1 Kang et al.
2004
Systematic review
and meta analysis 
of 11 RCTs (5936
patients)
PER (2–4 mg) plus IND
(0.625–1.25 mg) as one
daily tablet vs PLA 
(five studies)
PER (2–4 mg) plus IND
(0.625–1.25 mg) as one
daily tablet vs routine
AH therapiesa
(six studies)
Between-group WMDs
favored PER plus IND
–9.03 mmHg (95% CI –9.54,
–8.52), P<0.01 for overall
effect
Between-group WMDs
favored PER plus IND
–3.72 mmHg (95% CI –7.11,
–0.33), P=0.03 for overall
effect
Between-group WMDs favored
PER plus IND –5.09 mmHg
(95% CI –5.42, –4.77), P<0.01
for overall effect
Between-group WMDs favored
PER plus IND –1.71 mmHg
(95% CI –2.27, –1.16), P<0.01 
for overall effect
–
–
2 Asmar et al.
2001
RCT including 471
patients with
hypertension
PER (2 mg) plus IND
(0.625) as one daily
tablet vs ATL 
50 mg/day
22.0±15.6 mmHg reduction of
brachial BP with PER plus
IND vs 15.0±16.3 mmHg
reduction with ATL
12.6±8.9 mmHg reduction of
brachial BP with PER plus IND
vs 12.0±9.8 mmHg reduction
with ATL
–
2 PROGRESS
2001
RCT including
6105 patients (48%
hypertensive) with
prior stroke or TIA
PER (4 mg/d, all
patients) plus IND
(2–2.5 mg/d, 
58% patients) vs PLA
Mean follow-up 3.9 y
9.0±0.3 mmHg reduction with
active treatment vs PLA
12.3±0.5 mmHg reduction
with PER plus IND vs PLA
4.9±0.6 mmHg reduction with
PER alone vs PLA
4.0±0.2 mmHg reduction with
active treatment vs PLA
5.0±0.3 mmHg reduction with
PER plus IND vs PLA
2.8±0.3 mmHg reduction with
PER alone vs PLA
–
2 Mourad 
et al. 2004
9-month parallel
group study
including 
533 patients 
with hypertension
“Low-dose combination”
PER (2 mg)/IND 
(0.625 mg) 
“Sequential
monotherapy” ATL 
(50 mg), then LOS 
(50 mg), then AML (5 mg)
“Stepped-care” VAL
(40, 80 mg) ± HCT 
(12.5 mg)
– – More patients
achieved target
blood pressure 
with the “low-dose
combination” 
(62%) than with
“sequential therapy”
(49%, P=0.02) and
“stepped care”
(47%, P=0.004)
3 Speirs 
et al. 1998
47 351 patients in
1-y postmarketing
study 
PER (2, 4, or 8 mg/d)
for 1 y
Change over 1 y from
173±16.3 to 145±12.2 mmHg 
Change over 1 y from 100±8 to
82±8 mmHg
–
3 Cohn et al.
2004b
1412 African-
American patients
with hypertension 
PER (4 or 8 mg/d) 
for 12 w
Mean decrease from baseline
14.4 and 18.2 mmHg(P<0.001
vs baseline) after 12 w for
African-Americans and white
patients, respectively
Mean decrease from baseline
9.1 and 10.6 mmHg
(P<0.001 vs baseline) after 12 w
for African-Americans and white
patients, respectively
Achieved in 38.9%
of African-Americans
and 50.2% white
patients by w 12
3 Guo et al.
2004b
3159 patients
lacking BP control
from previous 
AH therapy  
PER (4 or 8 mg/d) 
for 12 w
Mean (±SE) decrease from
baseline 14.9 (±0.4) mmHg
(P<0.001 vs baseline) by w 12
Mean (±SE) decrease from
baseline 8.4 (±0.2) mmHg
(P<0.001 vs baseline) by w 12
Achieved in 40% of
patients by w 12
3 Julius 
et al. 2004
13 220 patients
with hypertension
in an OL, 
FP-based CT
PER (4 or 8 mg/d) 
for 12 w
Mean decrease from baseline
17.7 mmHg (P<0.001) after 
12 w
Mean decrease from baseline
10.5 mmHg (P<0.001) after 12 w
Achieved in 48.8%
of patients by w 12
3 Neutel et al.
2004b
3010 patients
>65 y with
hypertension
PER (4 or 8 mg/d) 
for 12 w
Mean decrease from baseline
18.4 mmHg (P<0.001 vs
baseline) after 12 w
Mean decrease from baseline
8.7 mmHg (P<0.001 vs baseline)
after 12 w
Achieved in 41.4%
of patients by w 12
aPerindopril monotherapy, perindopril plus low-salt diet, enalapril, losartan, atenolol, irbesartan; bSubstudy of Julius et al. 2004.
AH, antihypertensive; AML, amlodipine; ATL; atenolol; BP, blood pressure; CI, confidence interval; CT, clinical trial; d, day; DBP, diastolic blood pressure; FP, family practice;
HCT, hydrochlorothiazide; IND, indapamide; LOS, losartan; OL, open label; PLA, placebo; PER, perindopril; RCT, randomized controlled trial; SBP, systolic blood pressure; SE, standard error; 
TIA, transient ischemic attack; VAL, valsartan; w, week; WMD, weighted mean difference; y, year.69
Perindopril | clinical impact review
with the combination therapy (12.3/5.0 mmHg) than those treated
with perindopril alone (4.9/2.8 mmHg). 
The “low-dose combination” of perindopril 2 mg and indapamide
0.625 mg has also been shown to be more effective in achieving
target blood pressure compared with two other strategies 
(Mourad et al. 2004). In the “sequential monotherapy” group,
treatment was initiated with atenolol 50 mg, replaced if necessary by
losartan 50 mg and then by amlodipine 5 mg. Patients in the
“stepped-care” group were randomized to valsartan 40 mg
(increased to 80 mg if necessary) and with hydrochlorothiazide 
12.5 mg if needed. Significantly more patients treated with the 
“low-dose combination” (62%) achieved the target blood pressure
compared with “sequential monotherapy” (49%, P=0.02) and
“stepped care” (47%, P=0.005). The “low-dose combination” was
also significantly superior in achieving normal blood pressure
without adverse events (56%) than “sequential monotherapy” 
(42%,  P=0.002) and “stepped care” (42%, P=0.004). Note that
although the “low-dose combination” is available as a single
preparation in many European countries it is not available in the USA.
One of the consequences of combination therapy with perindopril
and indapamide is an amelioration of hemodynamic
characteristics of hypertension during aging. For example, arterial
stiffness leads to increasing pulse pressure with age, and this
parameter is associated with an increased risk of CVD,
particularly CHD. There is good evidence from a double-blind
randomized study involving 471 hypertensive patients that for the
same reduction in DBP, perindopril 2 mg plus indapamide 
0.625 mg decreased brachial SBP and pulse pressure
significantly more than atenolol 50–100 mg/day alone (adjusted
mean differences between groups –6.2±1.5 and –5.5±1.0 mmHg,
respectively;  P<0.001) (Asmar et al. 2001). Perindopril plus
indapamide-induced decreases in SBP and pulse pressure were
associated with changes in arterial hemodynamics, including a
decrease in aortic stiffness and limiting the effects of wave reflection
on the blood pressure in central arteries. In contrast, arterial
hemodynamics were less affected by atenolol as this treatment did
not decrease wave reflections (Asmar et al. 2001). 
In summary, the evidence clearly demonstrates that perindopril,
used as monotherapy or in low-dose combination with
indapamide, is able to achieve clinically effective reductions in
blood pressure and control of hypertension. 
Prevention of cardiovascular events
There is clear evidence from a number of large, well-designed,
randomized, controlled studies [EURopean trial On reduction 
of cardiac events with Perindopril in stable coronary Artery 
disease (EUROPA), PROGRESS, and Anglo-Scandinavian Cardiac
Outcomes Trial—Blood Pressure Lowering Arm (ASCOT-BPLA)]
that perindopril treatment is associated with reductions 
in cardiovascular outcomes in a number of different patient
populations and subgroups (Table 5).
Perindopril has been evaluated in one of the largest studies to
assess the management of patients with stable CHD (Fox 2003).
Results from the study showed that perindopril treatment
was associated with a statistically significant relative-risk
reduction (RRR) of 20% (P=0.0003) in the composite primary
endpoint (cardiovascular mortality, nonfatal MI, and successfully
resuscitated cardiac arrest). The composite outcome was
improved in patients of all ages, with and without hypertension, or
previous history of MI. Treatment benefit was also seen in patients
on existing lipid-lowering therapies as well as those taking beta
blockers.  Post-hoc analysis stratified patients into tertiles
according to risk assessment based on the association of risk
factors at baseline with occurrence of the primary composite
endpoint (Deckers et al. 2006), and indicated that treatment benefit
of perindopril was consistent regardless of absolute risk level.
When compared with placebo, secondary endpoints reduced with
perindopril treatment included a 14% reduction (P=0.0009) in
total mortality, nonfatal MI, unstable angina and cardiac arrest,
and a 39% reduction (P=0.002) in hospital admission for heart
failure. In addition, the risk of MI (fatal and nonfatal) was reduced
by 24% by perindopril treatment. It was estimated that one major
cardiovascular event would be prevented through treating
50 patients for 4 years with perindopril (Fox 2003). 
Results from the diabetic substudy of EUROPA [PERindopril
SUbstudy in coronary Artery disease and DiabEtes (PERSUADE)]
showed that perindopril tended to reduce major cardiovascular
events to a similar level to that seen in the overall EUROPA
population (Daly et al. 2005). Because of the smaller patient
population in the study, PERSUADE was not sufficiently powered
to detect statistically significant differences between the placebo
and active treatment groups. Nevertheless, the rates of major
cardiovascular events in the diabetic population (12.6% for
perindopril vs 15.5% for placebo) was almost twice that of the
overall study population (7.4% for perindopril vs 9.0% for
placebo) (Fox 2003). Thus, the high rate of events in the diabetic
population means that a RRR in this population of similar
magnitude to that in the overall population is associated with
greater absolute risk reduction (Daly et al. 2005).
Patients with a history of stroke or transient ischemic attack (TIA)
are also at risk from further cardiovascular (and cerebrovascular)
events. PROGRESS was designed to determine the effect of a
perindopril-based regimen in both hypertensive and
nonhypertensive patients with a history of stroke or TIA
(PROGRESS 2003a). Active treatment comprised a flexible regimen
which included perindopril 4 mg daily for all patients plus the
addition of indapamide at the discretion of the physician. Of the
total of 3051 patients randomized to active treatment, 1770 (58%)
received combination therapy, the remainder receiving perindopril
monotherapy. There was a good balance between active treatment
and placebo groups for all recorded characteristics at baseline.
However, those patients for whom combination therapy or double
placebo was planned tended to be younger, were more likely to be
male, hypertensive, have CHD, and were recruited sooner after
their qualifying cerebrovascular event than those for whom single
active drug or single placebo was intended (PROGRESS 2003a).
After 4 years of follow-up, active treatment reduced the risk of total
major coronary events (nonfatal MI or death due from CHD) by 26%
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Level of evidence Reference Design  Treatment and mean dose Outcomes
2 EUROPA
2003
RCT including 
12 218 patients with
stable CAD
PER (8 mg/d) vs PLA for 3 y
Mean follow-up period 4.2 y
• PER treatment resulted in RRR of 20% (95% CI 9%, 29%;
P=0.0003) in the composite primary endpoint (CV death, 
nonfatal MI, and cardiac arrest with successful resuscitation)
• Outcome was improved in all age groups and among patients 
± hypertension, diabetes, or with previous MI
• Treatment benefit seen in patients taking beta blockers and 
lipid-lowering therapy
• PER treatment associated with 14% reduction in total mortality,
nonfatal MI, unstable angina, and cardiac arrest 
(95% CI 6%, 21%; P=0.0009)
• PER treatment reduced hospital admission by 39% 
(95% CI 17%, 56%; P=0.002)
2 PROGRESS
2003a
RCT including 6105
patients with prior
stroke or TIA
PER (4 mg/d, all patients) 
plus IND (2–2.5 mg/d, 
58% patients) vs PLA
Mean follow-up 3.9 y
• RRR for total coronary events 21% (95% CI 6%, 33%; P=0.008)
with active treatment vs PLA
• RRR for major coronary events 26% (95% CI 6%, 42%; P=0.02)
with active treatment vs PLA
• RRR for nonfatal MI 38% (95% CI 14%, 55%) with active
treatment vs PLA
• Risk of major coronary events reduced in both hypertensive 
and nonhypertensive patients
• PER plus IND reduced risk of major coronary event by 35% 
(95% CI 12%, 52%); PER alone reduced risk of major coronary
event by 7% (95% CI –37%, 38%; P=0.2)
• RRR for CHF 26% (95% CI 5%, 42%; P=0.02) with active
treatment vs PLA
• PER plus IND reduced the risk of CHF by 34% (95% CI 7%,
53%) while PER alone reduced the risk of CHF by 16% 
(95% CI –19%, 41%; P=0.2)
2 Arima et al.
2005b
RCT including 
476 patients with
prior stroke or TIA
and AF at baseline 
PER (4 mg/d, all patients) 
plus IND (2–2.5 mg/d, 
58% patients) vs PLA
Mean follow-up 3.9 y
• Active treatment lowered mean BP by 7.3/3.4 mmHg 
• Active treatment reduced major vascular events by 38% 
(95% CI 6%, 59%)
2 Dahlöf et al.
2005
RCT including 
19 257 patients with
hypertension plus ≥3
other CV risk factors
(ASCOT-BPLA)
AML-based regimen 
(AML 5–10 mg ± PER 4–8 mg)
or ATL-based regimen (ATL
50–100 mg ± BFZ 1.25–2.5 mg)
• AML-based regimen achieved lower BP values compared with
ATL-based regimen throughout the study; mean difference
SBP/DBP 2.7/1.9 mmHg 
Outcomes reduced with AM ± PER vs ATL ± BFZ include:
• Nonfatal MI (incl. silent) plus fatal CHD [HR 0.90 (95% CI 0.79,
1.02; P=0.102)]; primary endpoint
• Nonfatal MI (excl. silent) plus fatal CHD [HR 0.87 (95% CI 0.76,
1.0; P=0.0458)]
• Total coronary endpoint [HR 0.87 (95% CI 0.79, 0.96; P=0.007)]
• Total CV events and procedures [HR 0.84 (95% CI 0.78, 0.90;
P<0.0001)]
• All-cause mortality [HR 0.76 (95% CI 0.65, 0.90; P=0.001)]
• CV mortality [HR 0.76 (95% CI 0.65, 0.90; P=0.001)]
• Fatal and nonfatal stroke [HR 0.77 (95% CI 0.66, 0.89; P=0.0003)]
2 Daly et al.
2005a
RCT including 1502
diabetic patients with
stable CAD
(PERSUADE)
PER (8 mg/d) vs PLA for 3 y • PER treatment resulted in a risk reduction [19% (95% CI –7%,
38%; P=0.13)] of similar magnitude in the composite primary
endpoint to that seen in the main EUROPA population
2 Sever et al.
2005
RCT including
10 305 patients with
hypertension plus ≥3
other CV risk factors
and cholesterol levels
≤6.5 mmol/L
(ASCOT-LLA)
AML-based regimen 
(AML 5–10 mg ± PER 4–8 mg) 
or ATL-based regimen 
(ATL 50–100 mg ± BFZ 
1.25–2.5 mg) + ATV 10 mg 
or PLA
• Primary endpoint reduced by 53% compared with placebo in 
the AML ± PER plus ATV group, but only by 16% in the ATL
± BFZ + ATV group
• Statistically significant interaction between blood pressure
lowering and lipid lowering was demonstrated (P=0.025)
3 CAFE
Investigators
2006c
RCT including 
2199 patients from
five ASCOT centers
AML-based regimen 
(AML 5–10 mg ± PER 4–8 mg) 
or ATL-based regimen 
(ATL 50–100 mg ± BFZ 
1.25–2.5 mg) over 4 y
• Similar reductions in BP for both treatment groups
(–26/–13.8 mmHg for ATL ± THZ; –27.8/–15.7 mmHg for AML ± PER)
• Significantly lower central aortic systolic pressure and central
pulse pressure for AML ± PER (AUC difference 4.3 mmHg and 
3.0 mmHg, respectively; P<0.0001)
3 Deckers 
et al. 2006d
Post-hoc analysis 
of RCT including 
12 218 patients with
stable CAD
PER (8 mg/d) vs PLA for 3 y
Mean follow-up period 4.1 y
• Risk reduction for the composite primary endpoint was
consistent for low-, intermediate-, and high-risk patients 
(HR 0.88, 0.68, and 0.83, respectively)
aSubstudy of EUROPA 2003; bSubstudy of PROGRESS 2003a; cSubstudy of ASCOT; dPost-hoc analysis of EUROPA 2003.
AF, atrial fibrillation; AML, amlodipine; ATL, atenolol; ATV, atorvastatin; AUC, area under the curve; BFZ, bendroflumethiazide; BP, blood pressure; CAD, coronary artery disease; CHD, coronary heart disease;
CHF, congestive heart failure; CI, confidence interval; CV, cardiovascular; d, day; DBP, diastolic blood pressure; HR, hazard ratio; IND, indapamide; MI, myocardial infarction; PER, perindopril; PLA, placebo;
RCT, randomized controlled trial; RRR, relative-risk reduction; SBP, systolic blood pressure; THZ, thiazide; TIA, transient ischemic attack; y, year.
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(P=0.02) and nonfatal MI by 38% (Table 5). This benefit was also
seen in a subpopulation of patients with atrial fibrillation where
active treatment was associated with a 38% reduction in major
vascular events (Arima et al. 2005). In addition, the reduction in risk
of major coronary events was similar in patients with or without
hypertension at baseline (PROGRESS 2003a). This demonstrates
clear benefits of treatment for high-risk, nonhypertensive
individuals as well as for those with hypertension. Among
participants treated with combination therapy (perindopril plus
indapamide), the risk of any major coronary event was lower than
in placebo-treated patients, but the risk was no different for patients
receiving perindopril monotherapy compared with placebo. It was
concluded that 5 years of treatment with perindopril plus
indapamide would have resulted in the avoidance of one major
nonfatal vascular event among every 11 patients [95% confidence
interval (CI) 9, 16] assigned active treatment (PROGRESS 2003a).
There is also evidence that a perindopril-based regimen reduces
the risk of CHF developing. Active treatment with the perindopril-
based regimen in the PROGRESS study reduced the risk of CHF
by 26% (P=0.02) and both hypertensive and nonhypertensive
patients benefited equally (27% risk reduction for both groups)
(PROGRESS 2003a). In addition, there was a nonstatistically
significant trend towards a greater risk reduction achieved with
combination therapy compared with perindopril alone (Table 5).
Recently published results from the large (19 257 patients) ASCOT-
BPLA have shown a greater benefit of an antihypertensive regimen
of CCB plus an ACE inhibitor compared with a beta blocker plus 
a diuretic for the prevention of adverse cardiovascular outcomes,
and less risk of induction of diabetes in hypertensive patients 
at moderate risk of developing cardiovascular events (Dahlöf et al.
2005) (Table 5). Patients were randomized to either amlodipine 
5–10 mg/day adding perindopril 4–8 mg/day as required
(amlodipine ± perindopril regimen, n=9639), or atenolol 
50–100 mg adding bendroflumethiazide 1.25–2.5 mg and potassium
as required (atenolol-based regimen, n=9618). At the end of the
trial, most patients (78%) were taking at least two antihypertensive
drugs and only 15% and 9% were taking amlodipine and atenolol
monotherapy, respectively. Throughout the study a mean of 59% of
patients were taking perindopril (9% alone plus 50% in combination
with another drug) and 70% of patients were taking atenolol (15%
alone plus 55% in combination with bendroflumethiazide).
ASCOT-BPLA was terminated early, after 5.5 years of follow-up, 
on recommendation of the data safety monitoring board 
because compared with those patients allocated the 
amlodipine ± perindopril regimen, those allocated the atenolol-
based regimen had significantly higher mortality plus worse
outcomes on several other endpoints. The likelihood of
hypertensive patients having a primary endpoint of nonfatal
(including silent) MI and fatal CHD were 10% lower (nonsignificant)
if they were treated with the amlodipine ± perindopril regimen
compared with the atenolol-based regimen. The study was
powered for 1150 patients to have such events, but in fact only
903 occurred by the time of the early termination. Although the
study was underpowered for this endpoint, it is likely that it would
have reached statistical significance had the study run its course.
Nevertheless, there were statistically significant (P≤0.05) reductions
in most of the secondary endpoints for patients randomized to 
the amlodipine ± perindopril regimen. These included nonfatal
(excluding silent) MI and fatal CHD (13% reduction), total coronary
events (13%), total cardiovascular events and procedures (16%),
all-cause mortality (11%), and cardiovascular mortality (24%). The
difference in all-cause mortality was attributable to cardiovascular
mortality as noncardiovascular mortality was similar for the two
treatments (475 and 478 deaths for the amlodipine ± perindopril
regimen and atenolol-based regimen, respectively). Patients
allocated to the amlodipine-based regimen were also 30% less
likely to develop diabetes compared with those allocated to
atenolol-based treatment (P=0.0001) (Dahlöf et al. 2005). 
Compared with patients randomized to the atenolol-based regimen,
blood pressure values were lower throughout the 5.5-year trial in
patients allocated the amlodipine ± perindopril regimen. Although
the differences were greatest after 3 months (5.9/2.4 mmHg), the
average difference was 2.7/1.9 mmHg throughout the study.
Perhaps surprisingly, a further analysis found no temporal link
between the degree of blood pressure reduction and event rates,
suggesting that factors other than blood pressure control may
produce the benefits observed (Poulter et al. 2005). However, in an
accompanying editorial, Staessen and Birkenhäger (2005) criticized
this analysis on the grounds of inappropriate exclusion of a number
of patients, and strongly suggested that blood pressure lowering
was responsible for most of the benefit seen in ASCOT.
Interestingly, a substudy of ASCOT, the Conduit Artery Function
Evaluation (CAFE) study, showed no difference in SBP between
the two treatment groups (CAFE Investigators 2006). However,
central aortic systolic pressure and central aortic pulse pressure
were significantly lower with amlodipine ± perindopril therapy than
with atenolol-based therapy. Modeling methods demonstrated a
significant relationship of central aortic pulse pressure to a
composite endpoint of cardiovascular events or procedures and
development of renal impairment (P<0.0001).
The lipid-lowering arm of ASCOT (ASCOT-LLA) added atorvastatin
10 mg or placebo to the amlodipine±perindopril or atenolol ±
bendroflumethazide regimens. The study showed that the benefits
of atorvastatin were modified by the concomitant antihypertensive
regimen (Sever et al. 2005). The primary endpoint was significantly
reduced (53%) in the amlodipine ± perindopril plus atorvastatin
group versus placebo, but only a nonsignificant reduction of 
16% was achieved in the atenolol ± bendroflumethazide plus
atorvastatin group. Other benefits for atorvastatin versus placebo
were also greater in the amlodipine ± perindopril group than in the
atenolol ± bendroflumethazide group.
In summary, it is established that along with other antihypertensive
agents, ACE inhibitors are able to prevent cardiovascular
complications in patients with hypertension (Turnbull 2003).
Although results from all studies are not completely consistent,
and it is of note that the results from ASCOT-BPLA are the subject
of considerable debate (Brady 2005; Hird 2005; Messerli &
Sichrovsky 2005; Staessen & Birkenhäger 2005; Williams 2005),
overall, the evidence presented here confirms that perindopril,
Core Evidence 2007;2(1)when used alone or as a component of a blood pressure-lowering
regimen, is effective in reducing cardiovascular complications in
patients with hypertension with or without other risk factors. 
Improvement in endothelial dysfunction
Perindopril was the only drug (of six antihypertensive drugs from
different classes) to improve endothelial function from baseline
values after 6 months of treatment (Ghiadoni et al. 2003). In 
this study involving 168 hypertensive patients, all treatments
reduced blood pressure to a similar degree, but only perindopril
increased flow-mediated dilation of the brachial artery (from
5.1±2.0% to 6.4±2.4%,  P<0.01) compared with normotensive
control subjects.
The reduction in cardiovascular events seen in EUROPA 
was greater than that expected for the observed reduction in
blood pressure (mean 5/2 mmHg) achieved with perindopril. It
was suggested that blood pressure lowering alone could not be
completely responsible for the observed benefits of the drug 
as the effects were similar in patients with or without
hypertension or whose blood pressure remained unchanged
during the study. This implies that other consequences of 
ACE inhibition, such as specific antiatherosclerotic effects
(improvement in endothelial function), may also be involved 
(Fox 2003). However, a substudy of EUROPA [PERindopril
Function of the Endothelium in Coronary artery disease Trial
(PERFECT)] (Bots et al. 2002) involving 333 patients failed to
show a statistically significant drug-related effect on endothelial
function (measured as flow-mediated vasodilation) (Bots et al.
2005). Instead a modest long-term improvement from baseline with
both perindopril and placebo was seen, with a nonsignificant
difference of 0.55% between the two treatment groups after 3
years (Bots et al. 2005). Reasons as to why the study failed to
show a statistically significant effect include heterogeneity in the
patient population plus severely diseased endothelium unable to
respond to treatment.
It must be considered that perindopril may not necessarily achieve
its beneficial effects via the endothelium. However, initial results
from another EUROPA subanalysis [(PERindopril, Thrombosis,
InflammatioN, Endothelial dysfunction and Neurohormonal
activation Trial (PERTINENT)] (Scientific Committee of the
PERTINENT substudy, EUROPA-PERTINENT subcommittee 2003)
provide indirect evidence that perindopril treatment does improve
endothelial function. Plasma markers of endothelial dysfunction
(von Willebrand factor and D-dimer) and systemic inflammation 
[C-reactive protein (CRP) and fibrinogen] were determined in 
this case-cohort study involving up to 1200 patients (Ceconi et al.
2005). At baseline, marker levels were at the upper range of normal
in the study population. After 1 year of treatment with perindopril
the markers of endothelial dysfunction, but not systemic
inflammation, were significantly reduced compared with placebo
(P<0.05). Another measure of endothelial function from the
PERTINENT study involved incubating serum from patients (n=98)
treated for 1 year with placebo or perindopril with human
umbilical vein endothelial cells in culture to mimic the effects 
of circulating blood on endothelial function (Ferrari 2004). 
The results showed that serum from treated patients restored the
bradykinin/AT II imbalance and reduced inflammatory marker
levels. For example, tumor necrosis factor alfa levels were
reduced to 24.6 pg/mL by serum from perindopril-treated patients
compared with 28.9 pg/mL (P<0.05) with serum from placebo-
treated patients. 
A randomized, double-blind, placebo-controlled study in 
18 obese healthy volunteers over 4 weeks did not show any effect
of perindopril 4 mg/day on flow-mediated vasodilation of the
brachial artery, although it did significantly lower blood pressure
compared with placebo (Williams et al. 2006). Obviously, this
study was limited by its small sample size and short treatment
duration. A further double-blind, randomized study examined
carotid distensibility after 7 months of treatment with perindopril
4 or 8 mg in 57 hypertensive patients with type 2 diabetes
(Tropeano et al. 2006). Blood pressure decreased in both groups,
with no significant difference between doses, but carotid
distensibility increased significantly more with perindopril 8 mg
than with perindopril 4 mg. Similarly, carotid internal diameter and
elastic modulus were significantly lower with the higher dose. 
The results suggest that perindopril reduces carotid stiffness
through inward remodeling, leading to a reduction in wall 
stress and thus reducing elastic modulus. These effects were
independent of the level of blood pressure reduction.
Therefore, there is some evidence that perindopril treatment 
does improve endothelial function in the clinic following
demonstrations that ACE inhibitors prevent endothelial
dysfunction in experiments in animals and humans (Thuillez et al.
1995; Mancini 2000). 
Prevention of cerebrovascular events 
There is evidence that active treatment with a perindopril-based
regimen (i.e. perindopril plus indapamide) reduces the likelihood
of further strokes in patients who have previously suffered
a stroke or a TIA.
In the ASCOT-BPLA study treatment, the amlodipine ± perindopril
regimen reduced the secondary outcome of risk of fatal and
nonfatal stroke by 23% (P=0.0003) compared with the atenolol-
based regimen (Dahlöf et al. 2005; Table 6). 
More direct evidence of the beneficial effect of perindopril on the
risk of stroke comes from the large multinational PROGRESS
study. One of the several outcomes of this study was to determine
the risk of stroke in patients treated with a perindopril-based
regimen versus placebo (PROGRESS 2001). After a mean follow-
up of 3.9 years it was found that active treatment significantly
reduced the risk of stroke by 28% when compared with placebo
(P<0.0001). This effect was not influenced by patients’ gender,
although there was some evidence that proportional risk
reductions were greater in patients aged under 65 years than in
older patients (Rodgers et al. 2004). Recurrent stroke risk was
also reduced by 38% in a subpopulation of patients with diabetes
(Berthet et al. 2004), and by 34% in patients with atrial fibrillation
at baseline in this study (Arima et al. 2005). In addition, stroke 
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risk was also reduced by 39% in participants of Asian origin
compared with 22% in Western participants (Rodgers et al. 2004).
With this regional difference in mind it is also notable that the 
risk of pneumonia was significantly reduced by active 
treatment among patients of Asian ethnicity (47%, P=0.01)
compared with non-Asians (5%, P=0.7) (Ohkubo et al. 2004). This
finding supports evidence from observational studies that ACE
inhibitors (but not other blood pressure-lowering drugs) reduce
the risk of pneumonia specifically among Asian populations
possibly through downstream effects of ACE polymorphisms
(Ohkubo et al. 2004). 
PROGRESS also showed that the annual rate of new incidences
of stroke in the total population was 2.7% with active treatment
and 3.8% in the control group (PROGRESS 2001). Compared with
placebo treatment, fewer patients in the active treatment group
had strokes that were fatal or disabling, and fewer in the active
group had severe strokes. In addition, perindopril treatment
reduced the risk of either ischemic stroke or cerebral hemorrhage
(risk reduction 24 and 50%, respectively) compared with placebo
treatment (Chapman et al. 2004). Among participants treated with
the combination of perindopril plus indapamide (58% receiving
active treatment) stroke risk was reduced by 43% compared with
placebo. In contrast, for patients treated with perindopril alone the
risk of stroke was reduced by only 5% compared with placebo.
Therefore, the markedly greater reduction in blood pressure
achieved with combination therapy compared with perindopril
alone (Table 4) appears to account for this difference in outcome.
This was further investigated in a post-hoc analysis evaluating the
effect of treatment according to blood pressure levels at baseline,
and levels achieved after treatment (Arima et al. 2006). The results
suggested that there were greater reductions in risk of stroke with
combination therapy than with perindopril alone, regardless of
blood pressure level at baseline. In addition, lower blood pressure
achieved during follow-up was strongly associated with a lower
risk of stroke. These data agree with findings that more intensive 
blood pressure lowering confers greater reductions in stroke risk 
(Neal et al. 2000; Turnbull 2003). 
Patient outcomes in terms of dementia and cognitive decline 
were also shown to benefit from active treatment in the
PROGRESS study (PROGRESS 2003b). The risk of dementia and
cognitive decline were improved by active treatment by 
12% (nonsignificant) and 19% (P=0.01), respectively. In addition,
the risk of the composite outcomes of dementia with recurrent
stroke and cognitive decline with recurrent stroke were reduced
by 34% (P=0.03) and 45% (P=0.001), respectively, following
active treatment. It is interesting to note that there was no
statistically significant effect of combination treatment compared
with single-drug therapy alone on the risk of any of these
outcomes. However, it is possible that too few events were
recorded in the subgroups to allow definitive conclusions to be
drawn (PROGRESS 2003b). Results from PROGRESS in part
counter the claims that an excessive fall in blood pressure may
actually increase the risk of silent brain infarct (SBI) and dementia
(Hasegawa et al. 2004). A substudy involving 667 patients within
PROGRESS was specifically designed to determine the risk of
SBI in the active and placebo-treated groups. The data showed
that moderate blood pressure lowering with the perindopril-based
regimen did not increase the risk of SBI and brain atrophy in
patients with a history of stroke (Table 6). Furthermore, reducing
DBP may actually decrease the risk of SBI irrespective of the type
of index stroke (i.e. the most recent stroke at the time of
randomization) (Hasegawa et al. 2004). A smaller PROGRESS
substudy also showed that active treatment stopped or delayed
the progression of cerebral white matter hyperintensities (WMH) 
in patients with stroke (Dufouil et al. 2005). WMH are often seen
in magnetic resonance images (MRI) from elderly patients or
those with stroke, and are associated with a number of outcomes
including cognitive impairment or dementia. Active treatment
reduced the risk of new WMH by 43% (P=0.17) compared 
with placebo in patients with an MRI at baseline and mean 
follow-up of 36 months. The mean volume of new WMH was also
decreased significantly with active treatment compared with
placebo, the difference being greatest for patients with severe
WMH at entry. 
Active treatment also reduced the odds of disability by 24%
(P<0.001) and dependency (“requirement of regular help with
everyday activities”) by 16% (P=0.04) in the PROGRESS trial
(PROGRESS 2003c). Thus, the effects of active treatment
appeared to be mediated primarily through the prevention of
disability and dependency associated with recurrent stroke. 
Four years of treatment with the perindopril-based regimen would
be expected to result in the avoidance of one case of long-term
disability for every 30 (95% CI 19, 79) patients (PROGRESS
2003c). There was no statistically significant difference between
combination therapy and perindopril alone for the prevention of
either disability or dependence.
In summary, perindopril-based treatment is effective in the secondary
prevention of stroke and associated disability and dependence.
There is also substantial evidence that cerebrovascular outcomes
including dementia and cognitive decline can be attenuated with
perindopril-based therapy.
Tolerability 
There is good evidence that perindopril is a well-tolerated
antihypertensive therapy. In common with other ACE inhibitors,
the most frequent adverse events seen with perindopril are dry
cough and gastrointestinal (GI) symptoms. These are typically
mild and reversible on treatment cessation. 
In a 12-month postmarketing survey involving 42 245 evaluable
patients (92% of the original cohort) treated with perindopril 
2–8 mg/day for 12 months, the most common spontaneously
reported clinical event was cough, in 9.6% (Speirs et al. 1998).
Other commonly described events were dyspepsia/GI upset
(1.9%), asthenia (1.8%), headache (1.4%), and dizziness/vertigo
(1.3%). Withdrawals due to suspected adverse reactions 
were reported in 2369 patients (total incidence 5%; 3.2% male
and 6.1% female patients). Fourteen serious adverse events 
were reported, including three cases of angiogenic edema, and 
11 serious allergic reactions. 
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Level of evidence Reference Design  Treatment and mean dose Outcomes
2 PROGRESS
2001
RCT including 
6105 patients with
prior stroke or TIA
PER (4 mg/d, all patients) plus
IND (2–2.5 mg/d, 58% patients)
vs PLA
Mean follow-up 3.9 y
• RRR for stroke 28% (95% CI 17%, 38%; P<0.0001) with active
treatment vs PLA
• Annual incidence of new stroke 3.8% with PLA vs 2.7% with
active treatment
• RRR for fatal or disabling stroke 33% (95% CI 15%, 46%) 
with active treatment vs PLA
• Combination therapy reduced stroke risk by 43% (95% CI 30%,
54%). PER alone reduced stroke risk by 5% (95% CI –19%, 23%)
• Risk of stroke reduced in both hypertensive and 
nonhypertensive patients
Rodgers 
et al. 2004
• Proportional risk reductions in stroke somewhat greater in
patients aged <65 y compared with those ≥65 y
• Risk of stroke reduced by 39% in Asian patients compared 
with 22% in Western patients
Ohkubo 
et al. 2004
• Risk of pneumonia reduced by 47% in Asian patients compared
with 5% in non-Asian patients
Chapman 
et al. 2004
• Reduced risk of recurrent stroke irrespective of the stroke
subtype: RRR all IS 24% (95% CI 10%, 35%); ICH 50% 
(95% CI 26%, 67%); unknown type 18% (95% CI –24%, 45%)
PROGRESS
2003b
RRRs for active treatment vs PLA:
• Dementia 12% (95% CI –8%, 28%; P=0.2) 
• Cognitive decline 19% (95% CI 4%, 32%; P=0.01)
• Dementia with recurrent stroke 34% (95% CI 3%, 55%; P=0.03)
• Cognitive decline with recurrent stroke 45% (95% CI 21%, 
61%; P<0.001)
PROGRESS
2003c
• Active treatment reduced the odds of disability and dependency
by 24% (OR 0.76; 95% CI 0.65, 0.89; P<0.001) and 16% 
(OR 0.84; 95% CI 0.71, 0.99; P<0.04), respectively
• NS difference between odds of disability or dependency 
with combination therapy or PER alone
2 Berthet 
et al. 2004a
RCT including 
761 patients 
with diabetes
PER (4 mg/d) ± IND (2–2.5 mg/d)
vs PLA
Mean follow-up 3.9 y
• Proportional risk reduction in stroke 38% (95% CI 8%, 58%) 
with active treatment vs PLA
• Absolute risk reduction for recurrent stroke in diabetic 
patients was equivalent to one stroke avoided among every 
16 (95% CI 9, 111) patients treated for 5 y
2 Hasegawa et
al. 2004a
RCT including 
667 patients with
prior stroke or TIA
PER (4 mg/d) ± IND (2 mg/d) 
vs PLA
Mean follow-up 3.9 y
• No difference in new SBI detected in PLA treated vs active
treated group (15 vs 12.5%, respectively; P=0.34)
• BP lowering with PER-based regimen did not increase risk of
SBI and brain atrophy in patients with stroke history. Reducing
DBP may decrease the risk of SBI
2 Arima et al.
2005a
RCT including 
476 patients with
prior stroke or TIA
and AF at baseline
PER (4 mg/d, all patients) plus
IND (2–2.5 mg/d, 58% patients)
vs PLA
Mean follow-up 3.9 y
• In patients with AF, active treatment reduced stroke by 
34% (95% CI –13%, 61%) vs PLA treatment
2 Dahlöf et al.
2005
RCT including 
19 257 patients 
with hypertension
plus ≥3 other CV 
risk factors 
(ASCOT-BPLA)
AML-based regimen 
(AML 5–10 mg ± PER 4–8 mg) 
or ATL-based regimen (ATL
50–100 mg ± BFZ 
1.25–2.5 mg)
• HR for AML- vs ATL-based regimen, fatal and nonfatal stroke
0.77 (95% CI 0.66, 0.89; P=0.0003)
2 Dufouil et al.
2005a
RCT including 
192 patients with
prior stroke or TIA
PER (4 mg/d) ± IND (2 mg/d) 
vs PLA
Mean follow-up 3 y
• More WMH developed in PLA vs active treated group 
(16 vs 9%, P=0.17)
• Volume of WMH was larger in PLA vs active treated group
(2.0±0.7 mm3 vs 1.8±0.5 mm3, P=0.012). The treatment effect 
on the total volume of new WMH was particularly marked in
patients with severe WMH at baseline (P<0.0001)
3 Arima et al.
2006b
Post-hoc analysis 
of RCT including
6105 patients with
prior stroke or TIA
PER (4 mg/d) ± IND (2–2.5 mg/d)
vs PLA
Mean follow-up 3.9 y
• Similar reductions in risk of stroke in four subgroups defined 
by baseline SBP (<120, 120–139, 140–159, ≥160 mmHg)
• Reduction in risk of stroke consistently higher with combination
therapy than with PER alone, regardless of baseline SBP 
• Lowest risk of stroke in subgroup with lowest follow-up SBP
levels; risks rose progressively with higher SBP levels
aSubstudy of PROGRESS 2001; bPost-hoc analysis of PROGRESS 2001.
AF, atrial fibrillation; AML, amlodipine; ATL, atenolol; BFZ, bendroflumethiazide; BP, blood pressure; CI, confidence interval; CV, cardiovascular; d, day; DBP, diastolic blood pressure; HR, hazard
ratio; ICH, intracerebral hemorrhage; IND, indapamide; IS, ischemic stroke; NS, not significant; OR, odds ratio; PER, perindopril; PLA, placebo; RCT, randomized controlled trial; RRR, relative-
risk reduction; SBI, silent brain infarct; SBP, systolic blood pressure; TIA, transient ischemic attack; WMH, white matter hyperintensities; y, year.
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Perindopril 8 mg/day was shown to be well tolerated in the
EUROPA study, which involved over 12 000 patients with CAD.
After 3 years, 81% of patients assigned to perindopril compared
with 84% assigned to placebo were still taking study medication.
Most patients who were assigned to perindopril continued on the
8 mg dose; only 7% had reduced to the 4 mg dose at 3 years.
After randomization, withdrawals from treatment were similar to
those for placebo; cough was a reason for withdrawals in 2.7% of
perindopril-treated patients compared with 0.5% treated with
placebo (Fox 2003). 
Perindopril-based treatment was also shown to be well tolerated
in the PROGRESS study in 6105 patients with a history of
previous stroke or TIA (PROGRESS 2001). Therapy was
continued in 86% of those assigned active treatment compared
with 87% assigned placebo. Premature discontinuation 
was similar between the two groups (active 23% vs placebo
21%). The main reasons for discontinuation were participant’s
decision (7.6 vs 8.2%), cough (2.2 vs 0.4%), and hypotension 
(2.1 vs 0.9%).
Economic evidence
There is some evidence regarding the cost effectiveness of
perindopril in the prevention of CVD based on data from the
EUROPA study. 
In one report the medical costs for CVD per patient were
estimated and cost per life-year gained per patient in the
Netherlands, France, Italy, and Poland was determined (Niessen
et al. 2005). The results showed that the life-years gained per
patient ranged from 0.182 to 0.209 per patient lifetime in the 
four countries and that the change in medical costs also ranged
from €462 to €1861 per patient. Thus the incremental cost-
effectiveness ratio (ICER) ranged from €2536 (in Poland) to €8904
(in Italy) per life-year gained. The probability that the ICER for 
a given country falls below a threshold value of €20 000 varied
from 73 to 92% and from 80 to 94% at a threshold of €30 000.
Therefore, the conclusion from the study was that given prevailing
ICER thresholds, perindopril is very likely to be cost effective. 
Data from the EUROPA study was also used to assess the cost
effectiveness of perindopril 8 mg in patients with stable CAD in
the UK (Briggs et al. 2006). The median incremental cost per
quality-adjusted life-year (QALY) across the heterogeneous study
population was estimated as £9500 (25th and 75th percentiles
£6500 and £14 400, respectively). Overall, 89% of the EUROPA
population had an incremental cost per QALY below £20 000 and
97% below £30 000.  
Resource utilization
One of the most important aspects of successful control of
hypertension is adherence to evidence-based therapeutic
guidelines. Adherence can lead to more effective control of blood
pressure and also has economic implications. In fact, there is
recent evidence that considerable cost savings can be achieved
if prescribing guidelines are followed. For example, a study
conducted in the USA analyzed actual versus potential regimens
for 133 624 elderly patients with hypertension in a large state
pharmaceutical assistance program (Fischer & Avorn 2004). 
In keeping with the JNC-7 guidelines, thiazide diuretics were
considered to be appropriate first-line therapy for hypertensive
patients without specific contraindications, with ACE inhibitors
being considered appropriate for hypertensive patients with CHF
or diabetes and nephropathy. The authors identified that 40% 
of all prescriptions could be substituted for a more appropriate
(i.e. guideline-recommended) regimen. Such substitution would
have resulted in potential savings of $US87.14 per person or
$US11.6 million per year for the program. Extrapolating these
results to the national level for this population would lead to savings
of $US1.2 billion per year in the USA. In addition to these savings
in drug acquisition, adherence to guideline recommendations
should also result in effective blood pressure control and
consequent reduction in the risk of costly complications. 
Although there is limited information on the cost effectiveness of
perindopril monotherapy or in combination, the fact that
perindopril (plus other antihypertensive agents) effectively reduces
blood pressure, one of a number of proven modifiable factors 
for CVD, suggests that the burden of CVD would be reduced 
with effective blood pressure management. The evidence shows
that perindopril-based therapies reduce cardiovascular and
cerebrovascular outcomes and that the prevention of these
outcomes will reduce resource necessary for their treatment. 
This will vary with the severity of the outcome, and may range from
additional drug therapy to costly emergency room treatment and
lengthy hospitalization. For example, there is clear evidence that
perindopril-based treatment reduces the risk of stroke. Thus,
reduction in the numbers of stroke patients requiring intensive
treatment, nursing or home help will have a beneficial impact on
use of limited resources. Similarly, reductions in the risk of
cognitive decline and dementia will also have an impact on the
burden on individuals and services managing these conditions.
Patient group/population
Treatment guidelines identify patients with blood pressure
≥140/90 mmHg (lower for patients with diabetes) as being
appropriate for antihypertensive therapy and/or reassessment on
a regular basis (Table 2). As has been reviewed in the Clinical
evidence section, perindopril (monotherapy and in combination
with indapamide) is effective in controlling hypertension in a
variety of patient groups, including those with type 2 diabetes,
dyslipidemia, isolated systolic hypertension, peripheral arterial
occlusive disease, and the elderly. In addition, beneficial blood
pressure control was seen in population of African-Americans
with hypertension (Cohn et al. 2004).
In the EUROPA study, all patients (mean age 60±9 years) 
had CHD, 27% had hypertension, and 12% were diabetic. 
In this large population, perindopril reduced the outcomes of
cardiovascular death, MI, cardiac arrest, acute coronary
symptoms, and the development of heart failure compared with
placebo treatment (Fox 2003). Similarly, the PROGRESS study
included 6105 randomized patients (mean age at study 
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the remainder an entry diagnosis of TIA alone. Nearly half (48%)
had hypertension and 12% had diabetes. Among this diverse
population of patients with a history of cerebrovascular events,
the perindopril-based blood pressure-lowering regimen reduced
the risk of stroke and other related outcomes compared with
placebo (PROGRESS 2001). This protective effect was also seen
in the specific populations with diabetes, and atrial fibrillation 
at baseline. 
The results from ASCOT-BPLA showed that the combination of
thiazide and beta blockers was inferior to the ACE inhibitor and
CCB combination for the total population and every subgroup
(Dahlöf et al. 2005). These findings support the current British
Hypertension Society (BHS) guidelines in the use of the AB/CD
treatment algorithm. The theory behind the algorithm is that
hypertension can be classified as “high” or “low” renin and is best
treated with drugs that inhibit [ACE inhibitors/ARBs (A), or beta
blockers (B)] or have no effect [CCBs (C) or diuretics (D)] on 
the renin-angiotensin system (Brown et al. 2003). A or B drugs
are more effective in blood pressure lowering in younger
Caucasian patients. In contrast, C or D drugs are less effective at
initial blood pressure lowering in these patients and are more
suitable in older Caucasians and black patients of any age
(Williams et al. 2004). 
Patients in ASCOT-BPLA were randomized to initial treatment
with either a CCB or beta blocker which was then augmented with
an ACE inhibitor or a thiazide diuretic in the respective arms.
However, in the clinic, according to the BHS guidelines a typical
participant in ASCOT-BPLA would be initiated on C (CCB) or 
D (thiazide diuretic) as initial therapy to give better initial control 
of blood pressure and would have advised against initial
treatment with a beta blocker or ACE inhibitor (Williams 2005). 
Yet the additional therapies would be considered appropriate, 
if not common, using the algorithm and have also been advocated
in the ESH/ESC guidelines (ESH/ESC 2003). On the other hand,
the combination of a beta blocker and a thiazide diuretic is not
generally recommended due to the increased risk of developing
type 2 diabetes (Williams et al. 2004). Indeed, results from
ASCOT-BPLA confirmed this as patients on the atenolol-based
regimen were 30% more likely to develop diabetes 
(Dahlöf et al. 2005). 
Therefore, the beneficial effect of perindopril has been shown in a
number of diverse populations that are representative of patients
with hypertension and other cardiovascular risk factors who are
likely to be encountered in the clinical environment.
Dosage, administration, and formulations
In the USA, perindopril is indicated for the treatment of essential
hypertension and in patients with stable CAD to reduce the risk 
of cardiovascular mortality or nonfatal MI. It is available as 2, 4, or 
8 mg tablets which should be taken in the morning before food. 
For the treatment of hypertension the recommended starting
dose is 4 mg once daily and may be titrated to a maximum of 
8 mg once daily to gain optimum blood pressure control. Elderly
patients and those with a strongly activated renin-angiotensin-
aldosterone system should be started on 2 mg once daily.
Patients already receiving diuretics should have this treatment
stopped 2–3 days before starting perindopril 2 mg. If required,
diuretics may be reinstated later at a lower dose. Coversyl 
Plus® (tablets containing perindopril 4 mg and indapamide 
1.25 mg) is indicated for patients in whom essential hypertension
is not adequately controlled by perindopril alone. However, this
preparation is not available in the USA. 
For the treatment of symptomatic heart failure the starting dose 
of perindopril is 2 mg, which may be increased to 4 mg if 
well tolerated, and is generally combined with a nonpotassium
sparing diuretic and/or digoxin and/or a beta blocker under 
close supervision. 
As with other ACE inhibitors, blood pressure, renal function, and
serum potassium should be monitored. In patients with impaired
renal function the dosage should be based on creatinine
clearance. When pregnancy is detected perindopril treatment
should be discontinued as soon as possible. In addition,
perindopril is also contraindicated in patients with a history of
angioedema related to previous treatment with an ACE inhibitor.
Perindopril is not recommended in children. 
Clinical value
The clinical evidence for perindopril covers both patient- and
disease-oriented outcomes as shown in the summary table at 
the beginning of this review.
There is clear evidence that perindopril, alone or in combination
with indapamide, achieves clinically significant reductions in 
SBP and DBP. In addition, there is evidence from one large,
community-based, open-label study that blood pressure control
was achieved in almost half of all hypertensive patients within 
12 weeks of starting treatment (Julius et al. 2004). The benefit
from reducing blood pressure with an antihypertensive agent is
the reduction in risk of the serious complications that may arise
from this condition (Turnbull 2003). Most evidence regarding the
reduction in morbidity and mortality associated with perindopril
has been obtained from the large EUROPA, PROGRESS, 
and ASCOT-BPLA studies which considered patient-oriented
outcomes in parallel with changes to blood pressure. Perindopril
treatment reduced cardiovascular mortality, MI, risk of CHF, and
cardiac arrest by 20% in patients with CAD irrespective of their
level of risk. The magnitude of this benefit was greater than that
predicted by the observed reduction in blood pressure in this
study. Investigations into this effect show that there is some
evidence supporting additional antiatherosclerotic effects and
improvements in endothelial function with perindopril. 
Evidence for beneficial effects of perindopril-based treatment on
cerebrovascular outcomes has come from the PROGRESS study
which has demonstrated significant reductions in the risk of stroke.
The greatest benefit was seen when blood pressure was lowered
more effectively by the combination of perindopril and indapamide
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compared with perindopril alone. PROGRESS substudies also
demonstrated that the risk of dementia, cognitive decline, and
disability were reduced by active treatment in this population. 
In the ASCOT-BPLA study, perindopril was used as an additional
therapy available to patients treated initially with the CCB
amlodipine. This study provided evidence that the better blood
pressure control achieved with the amlodipine ± perindopril
regimen therapy compared with atenolol-based treatment was
most likely responsible for the reduction in stroke, cardiovascular
events, and all-cause mortality. It is also possible that other
properties of perindopril including improvement in endothelial
function may have contributed to these clinical outcomes as well.
ASCOT-BPLA also confirmed that patients given the combination
of a beta blocker and thiazide diuretic are more likely to develop
diabetes compared with the combination of the newer classes of
antihypertensive agents. 
The question arises as to whether all the beneficial effects and
outcomes seen with perindopril in these large clinical studies are
drug specific, or are part of a class effect. The antihypertensive
effects of ACE inhibitors are well established as is their beneficial
effect on patients at high risk of CVD (Turnbull 2003). Nevertheless,
it remains to be confirmed whether the specific morbidity and
mortality-related outcomes from the EUROPA, PROGRESS, and
ASCOT-BPLA trials are specific for perindopril or may in part be
shared with other ACE inhibitors. In particular, the greater
reduction in cardiovascular events achieved with perindopril were
greater than the observed reduction in blood pressure suggested,
implying other drug-related effects. 
The question as to whether these effects are drug or class
specific cannot be answered definitively until similar clinical
studies are carried out with comparative drugs. However, the
likelihood of this occurring is remote mainly because of issues of
cost and motivation. Certainly there are physicochemical and
pharmacologic properties of perindopril that are not shared by
other ACE inhibitors and may account for its efficacy (Table 3). 
For example, it is likely that antiatherosclerotic effects depend on
perindopril’s affinity for tissue ACE in the endothelium and
lipophilicity allowing penetration of atherosclerotic plaques. Until
directly comparative trials with other ACE inhibitors are
conducted, in adherence to published guidelines regarding class
effects it is sensible to use only the clinically proven ACE inhibitor
when choosing an agent to improve the required outcome 
(e.g. risk reduction in cardiovascular event, stroke) (McAlister et
al. 1999). Given that there is a large body of evidence clearly
showing the benefits for perindopril-based treatment on these
outcomes then it would be prudent to use the proven perindopril-
based drug regimen to achieve them in the clinic.
Economic evidence for perindopril has been limited to cost-
effectiveness analyses from the EUROPA study. Reducing the 
risk of cardiovascular events, other morbidities, and mortality is
likely to have a beneficial economic outcome despite perindopril’s
high acquisition cost compared with other ACE inhibitors (on a
mg-to-mg basis) (Stoysich & Massoomi 2002). Whether perindopril
8 mg can be considered to be cost effective depends upon
individual healthcare systems’ threshold values for cost
effectiveness. The data from EUROPA showed that for most patients
the incremental cost per QALY gained was lower than threshold
values of €20 000 in Europe or £20 000 in the UK. Economic
analyses from other perindopril studies are awaited with interest. 
In summary, there is a large volume of good quality evidence
supporting the use of perindopril in the control of hypertension
and avoidance of associated complications. Although perindopril
alone may be used to reduce blood pressure, the fact that most
patients require two or more drugs to achieve current blood
pressure goals means that most monotherapy for hypertension is
usually inadequate (Williams et al. 2004). Recent evidence has
indicated that perindopril-based treatment is likely to have an
increasing role in the management of patients with hypertension,
stable CAD, or those at risk from further adverse cardiovascular
and cerebrovascular events. Further economic analyses are
needed to confirm its clinical value, particularly with respect to
other ACE inhibitors. Currently the evidence suggests that
perindopril is an effective intervention for reducing the burden 
of CVD.
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